Treatment of COVID-19 in Patients With Sarcoidosis

Kondle, Shreya; Hou, Titus; Manansala, Michael; Ascoli, Christian; Novak, Richard M.; Sweiss, Nadera J.

doi:10.3389/fmed.2021.689539

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older age, frailty, multimorbidity, and timing of contagion are, in fact, the main factors associated with adverse COVID-19 outcomes in the general population [ 102 , 103 ], and these associations probably remain valid also for patients with sarcoidosis [ 104 ].…”

Section: Treatment Approaches Algorithms For Suppression Of Sarcoidos...mentioning

confidence: 99%

Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation

Tana,

Cinetto,

Mantini

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been associated with dysregulation of the immune system featuring inappropriate immune responses, exacerbation of inflammatory responses, and multiple organ dysfunction syndrome in patients with severe disease. Sarcoidosis, also known as Besnier–Boeck–Schaumann disease, is an idiopathic granulomatous multisystem disease characterized by dense epithelioid non-necrotizing lesions with varying degrees of lymphocytic inflammation. These two diseases have similar clinical manifestations and may influence each other at multiple levels, eventually affecting their clinical courses and prognosis. Notably, sarcoidosis patients are at high risk of severe COVID-19 pneumonia because of the underlying lung disease and chronic immunosuppressive treatment. In this narrative review, we will discuss interactions between sarcoidosis and COVID-19 in terms of clinical manifestations, treatment, and pathogenesis, including the role of the dysregulated renin–angiotensin system, altered immune responses involving increased cytokine levels and immune system hyperactivation, and cellular death pathways.

show abstract

Section: Treatment Approaches Algorithms For Suppression Of Sarcoidos...mentioning

confidence: 99%

Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation

Tana,

Cinetto,

Mantini

et al. 2022

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In a retrospective review, the risk of hospitalisation or death from COVID-19 was not increased for patients with sarcoidosis compared with controls matched for age and comorbidities 25. While several other sarcoidosis-specific reports have been published, the findings are not widely applicable due to limitations such as small or non-diverse cohorts with non-severe disease,26–29 or selection bias in the other direction of limiting enrolment to hospitalised patients 28. Data from self-reported questionnaires given to patients with sarcoidosis offer some insight into the course of infection among patients fit enough to complete a survey,30 but the lack of a control group and an inability to verify data make extrapolation of outcomes to the general population with sarcoidosis difficult.…”

Section: Introductionmentioning

confidence: 99%

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study

et al. 2022

View full text Add to dashboard Cite

IntroductionRespiratory infections are ubiquitous. The COVID-19 pandemic has refocused our attention on how morbid and potentially fatal they can be, and how host factors have an impact on the clinical course and outcomes. Due to a range of vulnerabilities, patients with sarcoidosis may be at higher risk of poor outcomes from respiratory infections. The objective of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study is to determine the short-term and long-term impacts of respiratory viral illnesses (COVID-19 and non-COVID-19) in sarcoidosis.Methods and analysisUp to 20 clinical sites across the USA are participating in the recruitment of 2000 patients for this observational, prospective study. To ensure that the study cohort is representative of the general population with sarcoidosis, participating sites include those dedicated to reaching under-represented minorities or patients from non-urban areas. Baseline data on demographic features, comorbidities, sarcoidosis characteristics and pre-enrolment lung function will be captured at study entry. During this 3-year study, all acute respiratory infectious events (from SARS-CoV-2 and any other respiratory pathogen) will be assessed and recorded at quarterly intervals. The level of required medical care and survival outcomes determine infection severity, and the impact of infection on quality of life measures will be recorded. Post-infection lung function and imaging results will measure the long-term impact on the trajectory of sarcoidosis. Patients will be analysed according to the clinical phenotypes of cardiac and fibrotic pulmonary sarcoidosis. Control groups include non-infected patients with sarcoidosis and patients with non-sarcoidosis interstitial lung disease.Ethics and disseminationEach site received local institutional review board approval prior to enrolling patients, with the consent process determined by local institution standards. Data will be published in a timely manner (goal <12 months) at the conclusion of the 3-year follow-up period and will be made available upon request.

show abstract

Treatment of COVID-19 in Patients With Sarcoidosis

Cited by 3 publications

References 31 publications

Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation

Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study

Using bioinformatics and systems biology to discover common pathogenetic processes between sarcoidosis and COVID-19

Contact Info

Product

Resources

About